Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect

Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect

US Patent 12005120 · Granted Jun 11, 2024

Estimated economic value: $3,857,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Compounds targeting PMP22 for the treatment of Charcot-Marie-Tooth disease2025
Compositions comprising alternating 2′-modified nucleosides for use in gene modu2021
Compositions comprising alternating 2′-modified nucleosides for use in gene modu2019
Compositions comprising alternating 2′-modified nucleosides for use in gene modu2017
Methods of using IL-1β compounds to treat familial mediterranean fever (FMF)2017
5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom2015
Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflam2015
Compositions comprising alternating 2′-modified nucleosides for use in gene modu2015
Compositions comprising alternating 2'-modified nucleosides for use in gene modu2015
Tetrahydropyran nucleic acid analogs2015
Tetrahydropyran nucleic acid analogs2014
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom2014